Floatz logo

Luspatercept

Thrombocytopenia Due To Immune Destruction

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinicoprotein_peptideUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Thrombocytopenia Due To Immune Destruction cohort.

Asset / SponsorPhaseRating
Herombopag
Yin Jie
Phase 3B
Recombinant Human Thrombopoietin
Yin Jie
Phase 3B
Ogalvibart
Imperial College Healthcare NHS Trust
Phase 2CCC
Immunoglobulin G1-Lambda2, Anti-(Severe Acute Respiratory Syndrome (Human) Coronavirus 2 (Sars-Cov-2) Spike (S) Glycoprotein, Receptor Binding Domain (Rbd)), Homo Sapiens Monoclonal Antibod
Imperial College Healthcare NHS Trust
Phase 2CCC
her2bbζ/cd19t+ t cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1C
Fecal Microbiome
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
UnknownD
Erythropoietin
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
UnknownD

Same molecule, other indications

Luspatercept is also rated in:

anemiaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
beta-thalassemia majorActive
BB
Indicative · Phase 4
65 / 100
View asset →
beta thalassemiaActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →